Lexaria Bioscience Corp. LEXX Archives - Page 29 of 39

MondayApr 11, 2022 1:22 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Beginning of New Nicotine Formulation Creation, Evaluation Program

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has entered agreements with Altria Client Services LLC. According to the announcement, the agreements call for Lexaria to provide specific DehydraTECH(TM) powder-based nicotine formulations for a fee; Altria in turn will evaluate the formulations. The new agreements will continue through March 31, 2023. Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. In addition, the technology has shown the ability to increase bioabsorption with cannabinoids and nicotine by up to 10 times as well as decrease time…

FridayApr 08, 2022 2:29 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Hopes to Demonstrate DehydraTECH’s Superior Performance in Ongoing Epilepsy Research Program

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently announced the beginning of the first phase of its epilepsy research program, EPIL-A21-1. “The research program will assess the seizure-inhibiting activity of cannabidiol (‘CBD’) administered via the company’s proprietary DehydraTECH(TM) technology, compared to the only FDA-approved CBD-based seizure medication…. The EPIL-A21-1 research program contains two main studies to be performed in rodents following the first phase – a pilot animal model that has already begun. The main studies are slated to commence in May/June and involve an acute seizure model induced by electrical stimulation and chemically induced seizure models,” a recent article reads. “Using…

WednesdayApr 06, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Exploring Multiple Strong Market Paths

Lexaria is a global innovator that has developed the patented DehydraTECH(TM) technology that improves bioavailability, speed of onset, and brain absorption of active pharmaceutical ingredients (“APIs”) The company strategically partners with third-party organizations seeking to explore formulation opportunities with their specific APIs Lexaria is evaluating the effectiveness of various DehydraTECH-processed APIs, including CBD, nicotine, sildenafil, and more According to company CEO Chris Bunka, the management team is positioning the company to ensure that it has multiple paths to success In pursuit of multiple paths to success, Lexaria Bioscience (NASDAQ: LEXX), developer of the patented DehydraTECH(TM) drug delivery platform, strategically partners…

FridayApr 01, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Technology Continues to Showcase Ability to Improve Effectiveness of Existing Drug Brands

Health and wellness drug product innovator Lexaria Bioscience has developed a patented technology — DehydraTECH (TM) — which enhances the bioavailability of fat-soluble drugs and molecules Lexaria continues to research DehydraTECH’s ability to improve the speed and bioavailability of cannabidiol (“CBD”) in treating high blood pressure and epileptic conditions The company continues its research demonstrating the ability of its technology -to enhance the performance of antiviral drugs and other active pharmaceutical ingredients Sublicensing DehydraTECH continues to create revenues for the company Lexaria has additionally pursued the use of its drug-enhancing technology, in partnership with sublicensees, for making adult-use recreational cannabis…

WednesdayMar 30, 2022 2:27 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) 24th Patent Sets the Stage for New Market Opportunities in Australia

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, celebrated the receipt of its 24th granted patent entitled “Compositions Infused with Nicotine Compounds and Methods of Use Thereof.” Granted in Australia, this is the first patent awarded from the company’s 8th patent family. “The new patent expands on the company’s international IP rights to apply DehydraTECH(TM) technology to most forms of nicotine, namely sprays, gums, lozenges, pouches, capsules, tablets, and pills. It also covers multiple disparate forms of nicotine, including polymer resins of nicotine, freebase nicotine and other nicotine complexes,” reads a recent article. Prior to the…

FridayMar 25, 2022 3:40 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Optimistic About Its Upcoming, Largest-Ever Hypertension Study

Lexaria Bioscience Corp. (NASDAQ: LEXX) remains committed to enhancing the speed and efficiency of orally-delivered fat-soluble active molecules and drugs. “Through its patented DehydraTECH(TM) drug delivery technology that began development in 2014, the company is offering potential solutions for conditions including, but not limited to hypertension, smoking cessation, anti-viral treatments, and other drug classes,” reads a recent article. The piece discusses significant developments Lexaria has made with its HYPER-H21-4 clinical study on hypertension and heart disease treatment using DehydraTECH-CBD. Given the success of previous studies, the company announced plans for more trials over 2022. “During 2021, we completed research &…

TuesdayMar 22, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces First Phase of Epilepsy Research Using DehydraTECH(TM)-CBD

Lexaria’s patented DehydraTECH(TM) technology provides faster delivery times, increases bioavailability, increases brain absorption, improves drug potency, reduces administration costs, and masks unwanted flavors The epilepsy research will compare the FDA-approved Epidiolex(R) to the company’s proprietary DehydraTECH-CBD formulation The global cannabidiol (“CBD”) market had an estimated value of $2.7 billion in 2021 and is expected to reach $111.8 billion by 2030, driven by an increase in demand for CBD use in health and wellness industries Lexaria Bioscience (NASDAQ: LEXX) (NASDAQ: LEXXW), a global innovator in drug delivery platforms, recently announced that the first phase of its epilepsy research program, EPIL-A21-1, has…

MondayMar 21, 2022 9:15 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Intellectual Property Portfolio Grows Following Receipt of 24th Granted Patent

Lexaria has received a new patent entitled “Compositions Infused with Nicotine Compounds and Methods of Use Thereof” The new patent, granted in Australia, is the first awarded from Lexaria’s 8th patent family and offers IP protection across a total of 9 claims Lexaria believes the patent could be meaningful as it seeks to build value With the new patent, Lexaria’s IP portfolio has now grown to 24 granted patents worldwide In his letter to shareholders dated January 27, 2022, Lexaria Bioscience (NASDAQ: LEXX) CEO Chris Bunka documented the company’s expectation that it would receive additional patents in 2022. The expected…

TuesdayMar 15, 2022 3:36 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Commencement of DehydraTECH-CBD Epilepsy Research Program

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that the first phase of its epilepsy research program EPIL-A21-1 is beginning this week. According to the update, the DehydraTECH(TM)-CBD test articles needed to commence dosing have already been manufactured and delivered to the third-party laboratory engaged to complete this research program. EPIL-A21-1 will assess the seizure inhibiting activity of DehydraTECH-CBD compared to the world's only FDA-approved CBD-based seizure medication, Epidiolex(R). Lexaria hopes to demonstrate superior performance based on DehydraTECH’s known advanced drug delivery capabilities. Lexaria's seizure program expects to leverage the significant gains in systemic…

ThursdayMar 10, 2022 11:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX), a Global Innovator in Drug Delivery Platforms

Lexaria’s patented DehydraTECH technology proved effective for sildenafil delivery in animal study PDE5-A21-1 The company also made some notable strides with its HYPER-H21-4 clinical study on hypertension and heart disease treatment using DehydraTECH-CBD By doing so, it hopes to capitalize on the growing cardiovascular drugs market, which is projected to be valued at $107.8 billion by 2025 (https://ibn.fm/LwAUc) With the success of its studies thus far, the company seeks to conduct even more trials over the 2022 calendar year Lexaria Bioscience (NASDAQ: LEXX) has, since its inception, remained committed to enhancing the speed and efficiency of orally-delivered fat-soluble active molecules…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LEXX